Treatment and prevention of secondary CNS lymphoma

Seminars in Neurology

Volumn 30, Issue 3, 2010, Pages 263-272

  Nagpal, S ^a   Glantz, M J ^b   Recht, Lawrence ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

cerebrospinal fluid; CNS prophylaxis; non Hodgkin lymphoma; Secondary CNS lymphoma

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ARABINOSIDE; CORTICOSTEROID; CORTISONE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; METHOTREXATE; PREDNISOLONE; RITUXIMAB; THIOTEPA; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADD ON THERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOIMMUNOBLASTIC LYMPHOMA; B CELL ACUTE LEUKEMIA; BRAIN CANCER; BRAIN LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM; CENTROCYTIC CENTROBLASTIC LYMPHOMA; CEREBROSPINAL FLUID CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIFFUSE LARGE LYMPHOMA; HAIRY CELL LEUKEMIA; HIGH RISK POPULATION; HUMAN; IMMUNOBLASTIC LYMPHOMA; IMMUNOCYTOMA; INCIDENCE; INTESTINAL T CELL LYMPHOMA; LARGE CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTE LEUKEMIA; LYMPHOCYTOMA; LYMPHOPLASMACYTIC LYMPHOMA; MALT B CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; NONHUMAN; PATIENT SELECTION; PERIPHERAL T CELL LYMPHOMA; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PRIMARY MEDIASTINAL LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROLYMPHOCYTIC LYMPHOMA; REVIEW; RISK FACTOR; SEZARY SYNDROME; SPLENIC MARGINAL ZONE LYMPHOMA; T CELL LEUKEMIA; UNSPECIFIED SIDE EFFECT; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; CENTRAL NERVOUS SYSTEM TUMOR; METASTASIS; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE;

ANIMALS; CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; PRACTICE GUIDELINES AS TOPIC;

EID: 77954167987     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0030-1255222     Document Type: Review

References (66)

1. Horner MJRL, Krapcho M, Neyman N, et al SEER Cancer Statistics Review, 19752006. Bethesda, MD National Cancer Institute 2009
2. Colocci N, Glantz M, Recht L. Prevention and treatment of central nervous system involvement by non-Hodgkin's lymphoma: a review of the literature. Semin Neurol 2004 24 (4) 395-404
3. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000 11 (6) 685-690
4. Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002 13 (7) 1099-1107
5. Tomita N, Kodama F, Sakai R et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 2000 38 (3-4) 335-343
6. van Besien K, Ha C S., Murphy S et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998 91 (4) 1178-1184
7. Bernstein S H., Unger J M., Leblanc M, Friedberg J, Miller T P., Fisher R I. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 the Southwest Oncology Group. J Clin Oncol 2009 27 (1) 114-119
8. Jaffe ESHN, Stein H, Vardiman JW Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours Lyon, France IARC Press 2001
9. Hiddemann W, Longo D L., Coiffier B et al. Lymphoma classificationthe gap between biology and clinical management is closing. Blood 1996 88 (11) 4085-4089
10. Seki R, Ohshima K, Nagafuji K et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol 2010 91 (2) 258-266
11. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009 113 (17) 3896-3902
12. Villa D, Connors J M., Shenkier T N. et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010 21 (5) 1046-1052
13. Lim H Y., Thiel E, Glantz M J. To protect and defend: central nervous system prophylaxis in patients with non-Hodgkin's lymphoma. Curr Opin Oncol 2008 20 (5) 495-501
14. Recht L, Straus D J., Cirrincione C, Thaler H T., Posner J B. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 1988 84 (3 Pt 1) 425-435
15. Hegde U, Filie A, Little R F. et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005 105 (2) 496-502
16. Glantz M J., Cole B F., Glantz L K. et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998 82 (4) 733-739
17. Finn W G., Peterson L C., James C, Goolsby C L. Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry. Am J Clin Pathol 1998 110 (3) 341-346
18. Bromberg J E., Breems D A., Kraan J et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology 2007 68 (20) 1674-1679
19. Brem S S., Bierman P J., Black P et al. Central nervous system cancers. J Natl Compr Canc Netw 2008 6 (5) 456-504
20. Zeiser R, Burger J A., Bley T A., Windfuhr-Blum M, Schulte-Mnting J, Behringer D M. Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitisa single centre experience. Br J Haematol 2004 124 (6) 762-768
21. Strik H MPP, Pilgram-Pastor S, Buhk J H. Neoplastic meningitisIs MRI as sensitive as CSF cytology? Paper presented at: 2009 ASCO Annual Meeting May 29June 2, 2009 Orlando, FL
22. Su C S., Lan M Y., Chang Y Y., Lin W C., Liu K T. Clinical features, neuroimaging and treatment of spontaneous intracranial hypotension and magnetic resonance imaging evidence of blind epidural blood patch. Eur Neurol 2009 61 (5) 301-307
23. Chamberlain M C., Glantz M, Groves M D., Wilson W H. Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009 36 (4, Suppl 2) S35-S45
24. Kara I O., Sahin B, Gunesacar R. Levels of serum and cerebrospinal fluid soluble CD27 in the diagnosis of leptomeningeal involvement of hematolymphoid malignancies. Adv Ther 2007 24 (4) 741-747
25. Stockhammer G, Poewe W, Burgstaller S et al. Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology 2000 54 (8) 1670-1676
26. Roy S, Josephson S A., Fridlyand J et al. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol 2008 26 (1) 96-105
27. Zetterberg H, Andreasson U, Blennow K. CSF antithrombin III and disruption of the blood-brain barrier. J Clin Oncol 2009 27 (13) 2302-2303, author reply 23032304
28. Glantz M J., Hall W A., Cole B F. et al. Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer 1995 75 (12) 2919-2931
29. Brugires L, Le Deley M C., Rosolen A et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 2009 27 (6) 897-903
30. Grossman S A., Finkelstein D M., Ruckdeschel J C., Trump D L., Moynihan T, Ettinger D S., Eastern Cooperative Oncology Group. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. J Clin Oncol 1993 11 (3) 561-569
31. Glantz M J., LaFollette S, Jaeckle K A. et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999 17 (10) 3110-3116
32. Glantz M J., Van Horn A, Fisher R, Chamberlain M C. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010 116 (8) 1947-1952
33. Liu C Y., Teng H W., Lirng J F., Chiou T J., Chen P M., Hsiao L T. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma 2008 49 (10) 2018-2021
34. Villela L, Garca M, Caballero R, Borbolla-Escoboza J R., Bolaos-Meade J. Rapid complete response using intrathecal rituximab in a patient with leptomeningeal lymphomatosis due to mantle cell lymphoma. Anticancer Drugs 2008 19 (9) 917-920
35. Antonini G, Cox M C., Montefusco E et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 2007 81 (2) 197-199
36. Glantz M J., Jaeckle K A., Chamberlain M C. et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res 1999 5 (11) 3394-3402
37. Rubenstein J L., Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007 25 (11) 1350-1356
38. Pui C H., Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 2009 36 (4, Suppl 2) S2-S16
39. Kikuchi A, Kawada H, Iwaki Y et al. [Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma]. Rinsho Ketsueki 2004 45 (12) 1255-1257
40. Harjunp A, Wiklund T, Collan J et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001 42 (4) 731-738
41. Arkenau H T., Chong G, Cunningham D et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007 18 (3) 541-545
42. Boehme V, Zeynalova S, Kloess M et al, German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Incidence and risk factors of central nervous system recurrence in aggressive lymphomaa survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007 18 (1) 149-157
43. Goedert J J., Cot T R., Virgo P et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998 351 (9119) 1833-1839
44. Opelz G, Dhler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004 4 (2) 222-230
45. Bihan C L., Chevojon P, Doll J et al. Change in cause of death before and after introduction of highly active antiretroviral therapy (HAART): three general hospitals based study. Paper presented at: International Conference on AIDS July 712, 2002 Barcelona, Spain
46. Tirelli U, Spina M, Vaccher E et al. Clinical evaluation of 451 patients with HIV related non-Hodgkin's lymphoma: experience on the Italian cooperative group on AIDS and tumors (GICAT). Leuk Lymphoma 1995 20 (1-2) 91-96
47. Schrmann D DD, Dienemann D, Jautzke G et al. Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases. Klin Wochenschr 1991 69 (15) 679-686
48. Robotin M C., Law M G., Milliken S et al. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia. HIV Med 2004 5 (5) 377-384
49. Diamond C, Taylor T H., Im T, Miradi M, Anton-Culver H. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol 2006 24 (3) 139-145 (Pubitemid 44483907)
50. Palmieri C, Treibel T, Large O, Bower M. AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy. QJM 2006 99 (12) 811-826 (Pubitemid 46024093)
51. Navarro J T., Vall-Llovera F, Mate J L., Morgades M, Feliu E, Ribera J M. Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. Haematologica 2008 93 (1) 149-150
52. Spina M, Chimienti E, Martellotta F et al. Phase 2 study of intrathecal, long-acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2010 116 (6) 1495-1501
53. Caillard S, Agodoa L Y., Bohen E M., Abbott K C. Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 2006 81 (6) 888-895
54. Buell J F., Gross T G., Hanaway M J. et al. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc 2005 37 (2) 954-955
55. Alvarnas J C., Negrin R S., Horning S J. et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000 6 (3A, 3A) 352-358
56. Bokstein F, Lossos A, Lossos I S., Siegal T. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002 43 (3) 587-593
57. Kasamon Y L., Jones R J., Piantadosi S et al. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol Blood Marrow Transplant 2005 11 (2) 93-100
58. Jahnke K, Thiel E, Martus P, Schwartz S, Korfel A. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 2006 85 (1) 45-50
59. Matsumoto Y, Horiike S, Fujimoto Y et al. Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution. Int J Hematol 2007 85 (4) 333-337
60. Garcia-Marco J A., Panizo C, Garcia E S. et al. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer 2009 115 (9) 1892-1898
61. Chamberlain M C., Johnston S K., Van Horn A, Glantz M J. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 2009 91 (3) 271-277
62. Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high-dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol 2009 88 (2) 133-139
63. Chua S L., Seymour J F., Streater J, Wolf M M., Januszewicz E H., Prince H M. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002 43 (9) 1783-1788
64. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma. Cancer 2002 95 (3) 576-580
65. Tilly H, Lepage E, Coiffier B et al, Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003 102 (13) 4284-4289
66. Feugier P, Virion J M., Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004 15 (1) 129-133